EMPLOYMENT AGREEMENTEmployment Agreement • April 10th, 2007 • Aegerion Pharmaceuticals, Inc. • Pharmaceutical preparations • New Jersey
Contract Type FiledApril 10th, 2007 Company Industry JurisdictionThis EMPLOYMENT AGREEMENT (this “Agreement”) is dated as of the 1st day of July 2005, by and between Aegerion Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and William H. Lewis (the “Executive”).
UNIVERSITY of PENNSYLVANIA PATENT LICENSE AGREEMENTPatent License Agreement • April 10th, 2007 • Aegerion Pharmaceuticals, Inc. • Pharmaceutical preparations • Pennsylvania
Contract Type FiledApril 10th, 2007 Company Industry JurisdictionThis Patent License Agreement (this “Agreement”) is between The Trustees of the University of Pennsylvania, a Pennsylvania nonprofit corporation (“Penn”), and Aegerion Pharmaceuticals, Inc, a Delaware corporation (“Company”). This Agreement is effective on May 19, 2006 (the “Effective Date”).
LOAN AND SECURITY AGREEMENTJoinder Agreement • April 10th, 2007 • Aegerion Pharmaceuticals, Inc. • Pharmaceutical preparations • California
Contract Type FiledApril 10th, 2007 Company Industry JurisdictionTHIS LOAN AND SECURITY AGREEMENT is made and dated as of March 20, 2007 and is entered into by and between AEGERION PHARMACEUTICALS, INC., a Delaware corporation (“Borrower”), with its chief executive office and principal place of business located at 1140 Route 22 East, Suite 304, Bridgewater, NJ 08807 and HERCULES TECHNOLOGY GROWTH CAPITAL, INC., a Maryland corporation (“Lender”), with its principal place of business located at 400 Hamilton Avenue, Palo Alto, CA 94301.
ContractWarrant Agreement • April 10th, 2007 • Aegerion Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
Contract Type FiledApril 10th, 2007 Company Industry JurisdictionTHESE SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 AS AMENDED, OR ANY STATE SECURITIES LAWS. THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL (WHICH MAY BE COMPANY COUNSEL) REASONABLY SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED UNDER THE SECURITIES ACT OF 1933 ACT AS AMENDED, OR ANY APPLICABLE STATE SECURITIES LAWS.
LICENSE AGREEMENTLicense Agreement • April 10th, 2007 • Aegerion Pharmaceuticals, Inc. • Pharmaceutical preparations • New Jersey
Contract Type FiledApril 10th, 2007 Company Industry JurisdictionThis License Agreement (this “Agreement”), dated as of May 31, 2006 (the “Effective Date”), is made by and between Bayer HealthCare AG, a German corporation (“Bayer”), and Aegerion Pharmaceuticals, Inc., a Delaware corporation (“Aegerion”). Bayer and Aegerion are sometimes hereinafter referred to each as a “Party” and collectively as the “Parties.”
SECURED PROMISSORY NOTEAegerion Pharmaceuticals, Inc. • April 10th, 2007 • Pharmaceutical preparations
Company FiledApril 10th, 2007 IndustryThis Promissory Note is the Note referred to in, and is executed and delivered in connection with, that certain Loan and Security Agreement dated March 20, 2007, by and between Borrower and Lender (as the same may from time to time be amended, modified or supplemented in accordance with its terms, the “Loan Agreement”), and is entitled to the benefit and security of the Loan Agreement and the other Loan Documents (as defined in the Loan Agreement), to which reference is made for a statement of all of the terms and conditions thereof. All payments shall be made in accordance with the Loan Agreement. All terms defined in the Loan Agreement shall have the same definitions when used herein, unless otherwise defined herein. An Event of Default under the Loan Agreement shall constitute a default under this Promissory Note. Reference to the Loan Agreement shall not affect or impair the absolute and unconditional obligation of the Borrowers to pay all principal and interest and premium, if any